-+ 0.00%
-+ 0.00%
-+ 0.00%

Travere Therapeutics plans offering of $400 million convertible senior notes due 2032

PUBT·05/11/2026 21:11:09
Listen to the news
Travere Therapeutics plans offering of $400 million convertible senior notes due 2032
  • Travere Therapeutics launched an underwritten offering of USD 400 million convertible senior notes due 2032.
  • Deal includes a 30-day option for underwriters to buy up to an additional USD 60 million of notes, taking potential total issuance to USD 460 million.
  • Proceeds earmarked in part for cash repurchases of outstanding 2.25% senior convertible notes due 2029, with remaining funds for general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-217100), on May 11, 2026, and is solely responsible for the information contained therein.